Cissampelos pareira

Cissampelos pareira is an Ayurvedic medicinal plant containing alkaloids like hayatinine and hayatine that demonstrate anti-inflammatory and analgesic properties. The plant's ethanolic extract works by inhibiting inflammatory mediators and pain pathways in preclinical studies.

Origin & History

Cissampelos pareira L. is a tropical climbing vine from the Menispermaceae family, traditionally cultivated across South Asia and Southeast Asia. The plant is processed through various extraction methods including ethanol, methanol, and aqueous-ethanolic mixtures to produce bioactive preparations containing alkaloids (magnoflorine, pareirarine, cissamine, salutaridine), terpenoids, and saponins.

Historical & Cultural Context

Known as 'Laghupatha' in Sanskrit, Cissampelos pareira has been used for centuries in Ayurvedic medicine as a cooling, anti-inflammatory agent for treating pain, fever, inflammation, and diarrhea. The Dai people of southern Yunnan, China, have traditionally used the plant for managing diabetes.

Health Benefits

• Anti-inflammatory effects: 50% ethanolic extract (200-400 mg/kg) demonstrated significant anti-inflammatory activity in acute, subacute, and chronic rat models (PMID: 17097249) - evidence from animal studies only
• Pain relief: Ethanol extract showed 42.2-43.4% inhibition of acetic acid-induced writhing in mice at 250-500 mg/kg doses (PMID: 15050042) - preliminary animal evidence
• Antiviral activity: In vitro studies showed 98% inhibition of SARS-CoV-2 replication with whole extract, while isolated alkaloids exhibited 40-80% inhibition (PMID: 35459166) - in vitro evidence only
• Anticancer potential: Methanol extract demonstrated IC₅₀ of 95.5 μg/ml against Dalton's lymphoma ascites cells and increased lifespan by 54-72% in treated mice (PMID: 33485976) - preclinical evidence
• Anxiolytic effects: 70% hydroethanolic leaf extract (100-400 mg/kg) showed anxiolytic activity in murine models, though less potent than diazepam (PMID: 18280070) - animal model evidence

How It Works

Cissampelos pareira's alkaloids, particularly hayatinine and hayatine, appear to modulate inflammatory pathways by inhibiting pro-inflammatory mediators. The ethanolic extract demonstrates analgesic effects through inhibition of acetic acid-induced pain responses, suggesting interaction with nociceptive pathways. The anti-inflammatory activity likely involves suppression of acute and chronic inflammatory cascades.

Scientific Research

All available evidence for Cissampelos pareira is limited to preclinical and animal studies; no human clinical trials or meta-analyses have been published. Key studies include anti-SARS-CoV-2 activity in Vero cell cultures (PMID: 35459166), anti-inflammatory effects in rat models (PMID: 17097249), and anticancer activity in mice (PMID: 33485976).

Clinical Summary

Current evidence for Cissampelos pareira comes exclusively from animal studies with no human clinical trials available. In rat models, 50% ethanolic extract at 200-400 mg/kg showed significant anti-inflammatory activity across acute, subacute, and chronic inflammation models. The same extract demonstrated 42.2-43.4% inhibition of acetic acid-induced pain responses in animal studies. Human efficacy, safety, and optimal dosing remain unestablished due to lack of clinical research.

Nutritional Profile

Cissampelos pareira (Patha in Ayurveda) is a medicinal plant not consumed as a food source, so conventional macronutrient profiling (calories, protein, fat, carbohydrates, fiber) is not applicable. Its pharmacological relevance derives from its bioactive alkaloid and phytochemical content. Key compounds include: **Bisbenzylisoquinoline alkaloids** — hayatine (major alkaloid, ~0.2-0.5% dry weight of root), hayatinine, d-quercitol, pareirine (cissampeline), and cyclanoline; **Protoberberine alkaloids** — berberine (trace to low concentrations in root bark); **Triterpenoids and sterols** — β-sitosterol, stigmasterol; **Flavonoids** — quercetin, quercitrin, and rutin (leaves contain higher flavonoid content, estimated total flavonoids ~1.5-3.0 mg quercetin equivalents/g dry extract); **Tannins and phenolics** — total phenolic content approximately 25-45 mg gallic acid equivalents/g in 50% ethanolic root extract; **Saponins** — present in root and leaf tissues. The root is the primary part used in Ayurveda, rich in alkaloids (total alkaloid content approximately 0.5-1.2% dry weight). Mineral content of dried leaf/root includes calcium, potassium, magnesium, iron, and zinc in trace quantities, though precise values vary widely by geographic origin and are not standardized. No significant vitamin content has been documented. **Bioavailability notes:** Bisbenzylisoquinoline alkaloids such as hayatine have moderate oral bioavailability in animal models due to hepatic first-pass metabolism; ethanolic and hydroalcoholic extractions yield higher concentrations of bioactive alkaloids compared to aqueous decoctions. Traditional Ayurvedic preparations (kashaya/decoction or churna/powder) likely deliver lower alkaloid concentrations than standardized ethanolic extracts used in pharmacological studies.

Preparation & Dosage

Animal studies used: 250-500 mg/kg ethanol extract for pain/fever; 200-400 mg/kg 50% ethanolic extract for inflammation; 100-400 mg/kg 70% hydroethanolic extract for anxiety. No standardized human doses have been established. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Turmeric (anti-inflammatory), Boswellia serrata (joint health), Ginger (digestive support), Ashwagandha (adaptogenic support), Black pepper (bioavailability enhancement)

Safety & Interactions

Safety data for Cissampelos pareira in humans is extremely limited due to absence of clinical studies. Traditional use suggests general tolerability, but specific side effects, drug interactions, and contraindications have not been systematically evaluated. Pregnancy and breastfeeding safety is unknown and should be avoided without medical supervision. Individuals taking anti-inflammatory medications or pain relievers should consult healthcare providers before use due to potential additive effects.